Periodic Reporting for period 1 - ProMeta (Non-histone protein acetylation targets of KAT2A in AML)

Acute Myeloid Leukaemia (AML) has a dismal prognosis with less than 30% 5-year survival. Mainstay therapy has remained essentially unchanged for the past three decades, with small advances in disease-free survival for the most part attributable to transplantation and improved...